A Randomized, Controlled, Evaluator-blinded, Multi-center, Study to Evaluate LYS228 Pharmacokinetics, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Mar 2018
At a glance
- Drugs LYS-228 (Primary)
- Indications Urinary tract infections
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 05 Mar 2018 Planned End Date changed from 23 Dec 2018 to 1 Apr 2019.
- 05 Mar 2018 Planned primary completion date changed from 23 Dec 2018 to 1 Apr 2019.
- 05 Mar 2018 Planned initiation date changed from 18 Jan 2018 to 22 Mar 2018.